4340 Duncan Avenue St. Louis, MO 63110 314-615-6355 info@biogenerator.org

News

BioGenerator News

Backed by Atlas Venture, BioGenerator Company Indalo Therapeutics Begins Clinical Program

Apr 18, 2019

Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965  – Oral integrin antagonist inhibits multiple processes of pathologic fibrosis – Indalo to present at […]

Read More

BioGenerator Company Arch Oncology Closes $50M Series B to Develop Best in Class Anti-CD-47 Therapies

Mar 25, 2019

BRISBANE, Calif. and ST. LOUIS–(BUSINESS WIRE)–Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series […]

Read More

BioGenerator Company Benson Hill Biosystems Continues Rapid Growth by Acquiring Schillinger Genetics

Mar 19, 2019

ST. LOUIS, MO—March 19, 2019—Benson Hill Biosystems, a crop improvement company unlocking the natural diversity of plants, announced today at the World Agri-Tech Innovation Summit that it has acquired the […]

Read More

Vaccine Breakthrough Published in Nature Communications Highlights Research of Startup VaxNewMo

Feb 21, 2019

BioGenerator-supported startup noted for its ‘promising process’ to more quickly and affordably bring vaccines to market   St. Louis bioscience startup VaxNewMo is developing broader and more affordable vaccines faster with […]

Read More

BioGenerator Company Arch Oncology Doses First Cancer Patient in Phase 1 Clinical Trial

Feb 06, 2019

Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-class Profile — Phase 1 Clinical Trial to Evaluate AO-176 for the […]

Read More

BioGenerator and Bayer Growth Ventures Lead Financing for Agtech Startup CoverCress

Nov 14, 2018

Arvegenix Changes Name to CoverCress Inc.;  Secures $2 Million in New Financing for Novel Crop Development  ST. LOUIS (Nov. 14, 2018) – CoverCress Inc. (formerly Arvegenix Inc.), recently closed a $2 […]

Read More

BioGenerator Company MediBeacon Granted FDA Breakthrough Status

Oct 22, 2018

MediBeacon’s Breakthrough Device is Intended to Measure GFR in Patients with Impaired or Normal Kidney Function ST. LOUIS, Oct. 22, 2018 /PRNewswire/ — MediBeacon Inc., whose largest shareholder is Pansend Life […]

Read More

BioGenerator Company Cardialen Closes $17 Million Series B Financing for Heart Rhythm Therapy

Oct 10, 2018

CARDIALEN IS DEVELOPING A LOW-ENERGY IMPLANTABLE DEFIBRILLATION THERAPY DESIGNED TO MORE GENTLY RESTORE THE HEART TO A NORMAL RHYTHM. Minneapolis, Oct. 10, 2018 – Cardialen, Inc., a medical device company […]

Read More

BioGenerator Company Galera Therapeutics Raises $150 Million to Advance Breakthrough Therapy

Sep 19, 2018

Largest Series C venture round raised by a St. Louis bioscience company Galera Therapeutics, Inc., a clinical-stage drug discovery company, whose research and development is based in St. Louis, today […]

Read More

BioGenerator Company Benson Hill Biosystems Raises $60 Million Series C led by GV

Sep 10, 2018

BioGenerator portfolio company Benson Hill Biosystems, a crop improvement company unlocking the natural genetic diversity of plants, today announced the first close of its $60 million Series C financing.  BioGenerator was […]

Read More

Latest Tweets

Getting Started

Entrepreneurs Investors